Skip to main navigation Skip to search Skip to main content

Response by Piroth et al to Letter Regarding Article, "prognostic Value of Fractional Flow Reserve Measured Immediately after Drug-Eluting Stent Implantation"

  • Zsolt Piroth
  • , Gabor G. Toth
  • , Pim A.L. Tonino
  • , Emanuele Barbato
  • , Soheila Aghlmandi
  • , Nick Curzen
  • , Gilles Rioufol
  • , Nico H.J. Pijls
  • , William F. Fearon
  • , Peter Jöni
  • , Bernard De Bruyne

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Article numbere005973
JournalCirculation: Cardiovascular Interventions
Volume10
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Funding

The Cardiovascular Center Aalst receives grant support from Abbott, Boston Scientific, Biotronik, and St Jude Medical and receives consulting fees on behalf of Dr De Bruyne from St. Jude Medical, Opsens, and Boston Scientific outside of the submitted work. Dr De Bruyne is a shareholder for Siemens, GE, Bayer, Philips, HeartFlow, Edwards Life Sciences, Sanofi, and Omega Pharma. The other authors report no conflicts.

Keywords

  • Drug-Eluting Stents
  • Fractional Flow Reserve, Myocardial
  • Percutaneous Coronary Intervention
  • Prognosis

Cite this